The new head of Novartis UK thinks the country has gone backwards in terms of access to medicines, and says his company is moving towards 'payments for outcomes'. Haseeb Ahmad is the new managing ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

The global pharmaceutical drug delivery market is set to grow from USD 1,949.4 billion in 2024 to USD 2,546.0 billion by 2029 ...

Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

Would-be dads taking drugs to stop their epilepsy seizures—and valproate in particular—should be largely reassured that the available evidence on the developmental risks to their offspring doesn’t ...

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...